(Q33230098)

24 July 2017

1 reference

title

Selective delivery of therapeutic agents for the diagnosis and treatment of cancer (English)

1 reference

24 July 2017

Girja S Shukla

1

1 reference

24 July 2017

David N Krag

series ordinal

2

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

Expert Opinion on Biological Therapy

24 July 2017

published in

1 reference

24 July 2017

volume

6

1 reference

24 July 2017

issue

1

1 reference

24 July 2017

page(s)

39-54

1 reference

Ligand-targeted therapeutics in anticancer therapy

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Targeted therapy: wave of the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

The ErbB/HER receptor protein-tyrosine kinases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Recent progress in drug delivery systems for anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Cancer nanotechnology: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

In vivo cancer targeting and imaging with semiconductor quantum dots

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Monoclonal antibody therapy of haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Selective apoptotic killing of malignant hemopoietic cells by antibody-targeted delivery of an amphipathic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Tumour-targeted chemotherapy with immunoconjugates of calicheamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Genetically engineered antibodies for direct antineoplastic treatment and systematic delivery of various therapeutic agents to cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Engineering antibodies for clinical applications in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Molecular imaging and therapy directed at the neovasculature in pathologies. How imaging can be incorporated into vascular-targeted delivery systems to generate active therapeutic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

In vivo studies of Gd-DTPA-monoclonal antibody and gd-porphyrins: potential magnetic resonance imaging contrast agents for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Development of humanized antibodies as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Targeted gene delivery using humanized single-chain antibody with negatively charged oligopeptide tail

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Clinical applications of phage-derived sFvs and sFv fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Phage display technology: clinical applications and recent innovations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Therapeutic cancer targeting peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Peptides with anticancer use or potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Peptide aptamers: recent developments for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Phage display selection and evaluation of cancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

The use of phage display for the development of tumour targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Phage display selection for cell-specific ligands: development of a screening procedure suitable for small tumor specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Organ targeting in vivo using phage display peptide libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Molecular addresses in blood vessels as targets for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Nanocrystal targeting in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Gene expression imaging with radiolabeled peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Aptamers: an emerging class of therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Nucleic acid aptamers in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Selection of DNA aptamers against rat liver X receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Application of locked nucleic acids to improve aptamer in vivo stability and targeting function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Hypoxia--a key regulatory factor in tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Tirapazamine with cisplatin and vinorelbine in patients with advanced non-small-cell lung cancer: a phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Towards new transition metal-based hypoxic selective agents for therapy and imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Imaging hypoxia and angiogenesis in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Site-Specific Prodrug Activation by Antibody-.beta.-Lactamase Conjugates: Preclinical Investigation of the Efficacy and Toxicity of Doxorubicin Delivered by Antibody Directed Catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Chimeric TNT-3/human beta-glucuronidase fusion proteins for antibody-directed enzyme prodrug therapy (ADEPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

The kinetics of antibody binding to membrane antigens in solution and at the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

From bench to bedside for gene-directed enzyme prodrug therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. GLI328 European-Canadian Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Use of bacteria as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Salmonella-based tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET) for diagnostic imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Targeted adenoviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Secreted human beta-glucuronidase: a novel tool for gene-directed enzyme prodrug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

The present and future role of photodynamic therapy in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Targeted photodynamic therapy via receptor mediated delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Photodynamic therapy in superficial bladder cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Photodynamic therapy for esophageal cancer: a useful and realistic option.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Photodynamic therapy in the treatment of lung and oesophageal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Nanoshell-enabled photonics-based imaging and therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Magnetically modulated therapeutic systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Targeting liver tumors with hyperthermia: ferromagnetic embolization in a rabbit liver tumor model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Electromagnetic heating of breast tumors in interventional radiology: in vitro and in vivo studies in human cadavers and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Hepatocellular carcinoma: regional therapy with a magnetic targeted carrier bound to doxorubicin in a dual MR imaging/ conventional angiography suite--initial experience with four patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Spatial and temporal control of gene therapy using ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Targeting drug delivery to radiation-induced neoantigens in tumor microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Radiation-mediated control of drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Therapeutic applications of lipid-coated microbubbles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Evaluation of gas-filled microparticles and sonoporation as gene delivery system: feasibility study in rodent tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Delivery of systemic chemotherapeutic agent to tumors by using focused ultrasound: study in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Liver-targeted drug delivery using HepDirect prodrugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Tumour vascular targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Development of molecular targeted anticancer agents: successes, failures and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Molecular imaging applications in nanomedicine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Enzyme / Abzyme Prodrug Activation Systems: Potential Use in Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Spiegelmers: Biostable Aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Targeting therapeutic and imaging agents to folate receptor positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Discovering high-affinity ligands for proteins: SAR by NMR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Fragment-Based Drug Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Tethering: fragment-based drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Gene therapy clinical trials worldwide 1989-2004-an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Immunotargeted nanoshells for integrated cancer imaging and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

Principles of magnetodynamic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.1.39

21 January 2018

Identifiers

DOI

10.1517/14712598.6.1.39

1 reference

24 July 2017

1 reference